(NewsDirect)
Willow Bioscience CEO Dr Chris Savilejoined Steve Darling from Proactive to share a significantdevelopment. The company has unveiled a noteworthy partnership with aNasdaq-listed biopharmaceutical company, with a shared objective offorging precise and efficient manufacturing pathways for advancedintermediates and high-value active pharmaceutical ingredients (APIs).
Savile provided insights into thispartnership's progress, revealing that the initial phase of thefeasibility program, which leveraged Willow's BioOxiTM platform,surpassed expectations. In light of this success, the partner hascommitted to advancing the program further toward commercialization.This next phase will encompass additional research and developmentefforts, as well as scaling up production. One of the notable aspectsof this collaboration is the revenue-generating potential for WillowBioscience.
The company anticipatesrevenue streams from research fees, aligning perfectly with itsstrategic focus on near-term revenue generation from programs withrelatively short timelines for commercial revenue realization.Additionally, Willow expects to commence revenue generation from thecommercial supply of a crucial advanced intermediate through itsmanufacturing network as early as 2024.
This partnership represents a significant milestone for WillowBioscience, underscoring its commitment to advancing cutting-edgebiopharmaceutical solutions and capitalizing on opportunities in thepharmaceutical industry.
Savile also shared the company hasreported its third-quarter financials numbers that showed the companyhas seen record revenues for the third quarter and the signing of twonew program agreements, and advanced three programs to the next phaseof development toward commercialization.
ContactDetails
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.